Serum creatine as a biomarker for spinal muscular atrophy progression


  • The severity of spinal muscular atrophy (SMA) is associated with serum creatine (Crn) levels; thus, Crn could be used as a biomarker for disease progression in SMA.

Why this matters

  • Simple biomarkers that can monitor SMA disease onset, progression and treatment response are currently lacking.

  • In the future, the measurement of Crn should be part of routine analysis and monitoring of people with SMA.